Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994
Aisen, 2003, Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial, JAMA, 289, 2819, 10.1001/jama.289.21.2819
Thal, 2005, A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment, Neuropsychopharmacology, 30, 1204, 10.1038/sj.npp.1300690
Weggen, 2001, A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity, Nature, 414, 212, 10.1038/35102591
Eriksen, 2003, NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo, J Clin Invest, 112, 440, 10.1172/JCI18162
Lim, 2000, Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease, J Neurosci, 20, 5709, 10.1523/JNEUROSCI.20-15-05709.2000
Lleo, 2004, Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation, Nat Med, 10, 1065, 10.1038/nm1112
Beher, 2004, Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism, J Biol Chem, 279, 43419, 10.1074/jbc.M404937200
Golde, 2003, Alzheimer disease therapy: can the amyloid cascade be halted?, J Clin Invest, 111, 11, 10.1172/JCI200317527
Morihara, 2002, Selective inhibition of Abeta42 production by NSAID R-enantiomers, J Neurochem, 83, 1009, 10.1046/j.1471-4159.2002.01195.x
Geisslinger, 2000, Inhibition of noxious stimulus-induced spinal prostaglandin E2 release by flurbiprofen enantiomers: a microdialysis study, J Neurochem, 74, 2094, 10.1046/j.1471-4159.2000.0742094.x
Holm, 1979, A simple sequentially rejective multiple test procedure, Scand J Stat, 6, 65
Black, 2006, Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Ab42-lowering agent, in mild Alzheimer's Disease (AD): results of a 12-month phase 2 trial and 1-year follow-on study, Neurology, 66, A347
Siemers, 2006, Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease, Neurology, 66, 602, 10.1212/01.WNL.0000198762.41312.E1
El Mouedden, 2006, Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors, Curr Pharm Des, 12, 671, 10.2174/138161206775474233
Cirrito, 2003, In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life, J Neurosci, 23, 8844, 10.1523/JNEUROSCI.23-26-08844.2003
Bateman, 2006, Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo, Nat Med, 12, 856, 10.1038/nm1438
Yan, 2003, Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease, J Neurosci, 23, 7504, 10.1523/JNEUROSCI.23-20-07504.2003
Jantzen, 2002, Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice, J Neurosci, 22, 2246, 10.1523/JNEUROSCI.22-06-02246.2002
Yao, 2004, Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis, J Neuroinflamm, 1, 1, 10.1186/1742-2094-1-21